Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vikram Gopal

Gastroenterology Jacksonville, FL Medical Doctor

NPI 1720041247 CMS profile 78276

4800 Belfort Road, 2Nd Floor, Jacksonville, FL 32256

Open in the dashboard

General payments

$14,143

246 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$32,121 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Vikram Gopal of Jacksonville, FL is reported in the CMS Open Payments database as having received $14,143 across 246 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $32,121 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,107 53
2024 General $4,277 58
2023 General $957 45
2022 General $722 33
2021 General $809 28
2020 General $412 13
2019 General $860 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vikram Gopal
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Vikram Gopal were reported at $6,107. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Vikram Gopal Gastroenterology median Middle half National median
2019 $860 $417 $126–$1,100 $163
2020 $412 $224 $74–$624 $114
2021 $809 $352 $106–$1,054 $132
2022 $722 $448 $129–$1,270 $149
2023 $957 $533 $150–$1,390 $160
2024 $4,277 $605 $160–$1,606 $164
2025 $6,107 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,227 42 payments
  2. Medtronic, Inc. $3,116 25 payments
  3. Enterra Medical, Inc. $2,737 11 payments
  4. AbbVie, Inc. $1,268 65 payments
  5. Madrigal Pharmaceuticals $428 5 payments
  6. Janssen Scientific Affairs, LLC $347 3 payments
  7. Intercept Pharmaceuticals, Inc. $219 8 payments
  8. Janssen Biotech, Inc. $188 11 payments
  9. Apollo Endosurgery US Inc $181 3 payments
  10. Gilead Sciences, Inc. $180 10 payments
  11. Other $1,252 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,341 223 payments
  2. Travel and Lodging $6,781 22 payments
  3. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. GI Genius $2,964 24 payments
  2. OverStitch Endoscopic Suturing System $2,335 6 payments
  3. RINVOQ $429 23 payments
  4. REZDIFFRA $410 4 payments
  5. SKYRIZI $381 19 payments
  6. SPYGLASS $380 1 payment
  7. OverStitch NXT Endoscopic Suturing System $377 2 payments
  8. STELARA $364 10 payments
  9. CREON $355 16 payments
  10. LINZESS $302 18 payments
  11. Other $3,363 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

544

Median for Gastroenterology: 569

Drug cost

$204,981

Median for Gastroenterology: $104,976

Branded share of claims

14.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 22 $120,337
Zenpep Lipase/Protease/Amylase Brand 15 $64,298
Mesalamine Generic 11 $6,452
Omeprazole Generic 148 $3,455
Pantoprazole Sodium Generic 136 $2,907
Mesalamine Er Mesalamine Brand 12 $1,750
Balsalazide Disodium Generic 13 $1,320
Famotidine Generic 71 $1,319
Sucralfate Generic 46 $1,288
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 20 $1,251

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$231,420

Of which drugs: $90,942

Medicare patients

684

Average age 74

Services billed

8,998

381 women, 303 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 44%
Diabetes 35%
Chronic kidney disease 35%
Depression 29%
Atrial fibrillation 25%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 24 1,800 $44,368
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 14 1,090 $118
Infusion, normal saline solution, 250 cc J7050 Office 32 89 $46
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 12 196 $45
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 15 21 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $123
$123 — —
STELARA
  • Janssen Biotech, Inc. $113
$113 — —
SKYRIZI
  • AbbVie, Inc. $104
$104 — —
DUPIXENT
  • GENZYME CORPORATION $50
  • Regeneron Healthcare Solutions, Inc. $39
$89 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record